Claims
- 1. An isolated nucleic acid molecule comprising consecutive nucleotides having a sequence set forth in SEQ ID NO:6, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29 or SEQ ID NO:31 or comprising nucleotides having a sequence incorporated in plasmids deposited under ATCC Accession Nos. PTA-3638, PTA-3876, PTA-3877, PTA-3878 complements thereof or a polynucleotide having a sequence that differs due to the degeneracy of the genetic code from SEQ ID NO:6, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:31 or a sequence incorporated in plasmids deposited under ATCC Accession Nos. PTA-3638, PTA-3876, PTA-3877or PTA-3878, or a sequence which hybridizes under stringent conditions to SEQ ID NO:6, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29 or SEQ ID NO:31 or to a sequence incorporated in plasmids deposited under ATCC Accession Nos. PTA-3638, PTA-3876, PTA-3877or PTA-3878 or a functional portion thereof or a polynucleotide which is at least substantially homologous thereto.
- 2. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises a polynucleotide having at least 15, preferably at least 30, more preferably at least 50 contiguous nucleotides from SEQ ID NO:6, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29 or SEQ ID NO:31 or from the sequence incorporated in plasmids deposited under ATCC Accession PTA-3638, PTA-3876, PTA-3877 or PTA-3878.
- 3. A composition comprising the isolated nucleic acid molecule of claim 1.
- 4. A vector comprising the isolated nucleic acid molecule of claim 1.
- 5. A composition comprising the vector of claim 4.
- 6. A method for preparing a polypeptide comprising expressing the isolated nucleic acid molecule of claim 1 under suitable conditions and isolating the polypeptide.
- 7. A method for preparing a polypeptide comprising expressing the polypeptide from the vector of claim 4 under suitable conditions and isolating the polypeptide.
- 8 The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a 10 kD to 100 kD N-terminal cleavage product of the 608 protein.
- 9. The isolated nucleic acid molecule of claim 11, wherein the N-terminal cleavage product comprises a polypeptide of about 25 kD to about 80 kD.
- 10. The isolated nucleic acid molecule of claim 1 comprising consecutive nucleotides having a sequence set forth in SEQ ID NO:31.
- 11. The isolated nucleic acid molecule of claim 1 comprising consecutive nucleotides having a sequence set forth in SEQ ID NO:29.
- 12. An isolated polypeptide encoded by the polynucleotide of claim 1.
- 13. The isolated polypeptide of claim 12, wherein the polypeptide is identified as human protein 608, or a functional portion of protein 608 or Adlican-2, or a polypeptide which is at least substantially homologous thereto.
- 14. The isolated polypeptide of claim 13, wherein the polypeptide comprises about 663 to about 1634 amino acids.
- 15. An antibody which specifically binds to a polypeptide of claim 13 or a functional portion thereof.
- 16. An isolated polypeptide wherein the functional portion comprises consecutive amino acids having a sequence set forth in SEQ ID NO:16, SEQ ID NO: 24, SEQ ID NO: 30 or SEQ ID NO: 32.
- 17. The isolated polypeptide of claim 16 wherein the sequence comprises about the first 663 amino acids of the sequence set forth in SEQ ID NO:16, SEQ ID NO: 24, SEQ ID NO: 30 or SEQ ID NO: 32.
- 18. The isolated polypeptide of claim 17 wherein the sequence comprises about the first 741 amino acids of the sequence set forth in SEQ ID NO:16, SEQ ID NO: 24, SEQ ID NO: 30 or SEQ ID NO: 32.
- 19. The isolated polypeptide of claim 16, wherein the polypeptide is identified as human 608 protein or human Adlican-2 protein or a functional portion thereof or a polypeptide which is at least substantially homologous thereto.
- 20. An isolated polypeptide of claim 16 comprising consecutive amino acids having a sequence set forth in SEQ ID NO:32, designated human 608 protein.
- 21. An isolated polypeptide of claim 16 comprising consecutive amino acids having a sequence set forth in SEQ ID NO: 30 designated Adlican-2 polypeptide.
- 22. An isolated polypeptide of claim 21 comprising consecutive amino acids having a sequence set forth in SEQ ID NO: 30 deleted of amino acids 6-215.
- 23. An antibody which binds specifically to a polypeptide of claim 20.
- 24. An antibody which binds specifically to a polypeptide of claim 21.
- 25. An antibody of claim 23, which does not bind specifically to a rat 608 polypeptide.
- 26. An antibody of claim 25, wherein the rat polypeptide has a sequence set forth in SEQ ID NO: 34.
- 27. A composition comprising the antibody of claim 25
- 28. An expression plasmid selected from the group consisting of the plasmids pCm-H608-663Nterm, pKS H608 5′-2.4Kb bAc#1, pKS H608 m.FRG.3.5Kb#34 and pM H608 3′-1.9Kb HSTG#3.3, corresponding to plasmids deposited under ATCC Accession Nos.PTA-3638, PTA-3878, PTA-3876 and PTA-3877 respectively.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation-in-part of International Application No.PCT/US01/46400, filed Dec. 4, 2001, the entire contents of which are hereby incorporated by reference, and also a continuation-in-part of U.S. patent application Ser. No. 09/312216, filed May 14, 1999, the entire contents of which are also hereby incorporated by reference . Each document or reference cited in those applications is hereby expressly incorporated herein by reference. Documents or references are also cited in the following text, and these documents or references (“herein-cited documents or references”), as well as each document or reference cited in each of the herein-cited documents or references, are hereby expressly incorporated herein by reference.
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
PCT/US01/46400 |
Dec 2001 |
US |
Child |
10454351 |
Jun 2003 |
US |
Parent |
09312216 |
May 1999 |
US |
Child |
10454351 |
Jun 2003 |
US |